Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical sector with annual global sales of over US $70 billion. Medicure was founded in 1997 by the renowned cardiovascular researcher, Naranjan S. Dhalla, Ph.D., Professor and Director, Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, University of Manitoba and by internationally recognized biotech entrepreneur, Albert D. Friesen, Ph.D. (President and CEO). Medicure became a public company in November 1999 and trades under the symbol MPH on the Toronto Stock Exchange (TSX) and MCU on the American Stock Exchange (Amex).

Contact Information

4-1200 Waverley Street
Winnipeg, MBR3T0P4

tel: 204-487-7412
fax: 204-488-9823


Investor Relations



Exchange: AMEX
Industry: Biotechnology
Market Cap: $8.9M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.